左旋瓜氨酸治疗脊髓灰质炎后综合征患者:单中心、随机、安慰剂对照、双盲试验的研究方案
这是一项在瑞士招募30例可行走脊髓灰质炎后综合征患者的单中心、随机、安慰剂对照、双盲IIa期试验,按安慰剂与活性药物1:1随机分组,先进行24周导入期观察自然病史,再治疗24周,主要终点为6分钟步行距离试验变化,次要终点包括运动功能量表、定量肌力、定量肌肉磁共振成像与磁共振波谱及血清生物标志物。
要点
- 纳入30例可行走的脊髓灰质炎后综合征患者,随机1:1分配至左旋瓜氨酸组或安慰剂组。
- 先24周导入期观察自然病史,再治疗24周,主要终点为6分钟步行距离试验变化。
- 次要终点含运动功能量表、定量肌力、定量肌肉磁共振成像与波谱及血清生物标志物。
核心结论
- 该IIa期试验旨在确定左旋瓜氨酸治疗是否对脊髓灰质炎后综合征患者的临床功能和旁临床生物标志物显示积极效果。
- 若左旋瓜氨酸治疗显示积极效果,可能代表一种成本高效的脊髓灰质炎后综合征对症治疗。
研究设计与样本
- 研究者发起的单中心、随机、安慰剂对照、双盲试验,在瑞士招募30例可行走的脊髓灰质炎后综合征患者。
- 患者按安慰剂与活性药物1:1随机分配至两组。
- 先进行24周导入期观察自然疾病史与进展,随后接受左旋瓜氨酸或安慰剂治疗24周。
- 主要终点为6分钟步行距离试验的变化。
- 次要终点包括运动功能量表、定量肌力、定量肌肉磁共振成像与磁共振波谱及血清生物标志物实验室分析。
关键数值与推荐
- 主要终点为6分钟步行距离试验变化。
- 次要终点包括运动功能量表、定量肌力、定量肌肉磁共振成像与磁共振波谱及血清生物标志物实验室分析。
- 试验注册于ClinicalTrial.gov,ID:NCT02801071,注册日期2016年6月6日。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Post-polio syndrome (PPS) is a condition that affects polio survivors years after recovery from an initial acute infection by the Poliomyelitis virus. Most often, patients who suffered from polio start to experience gradual new weakening in muscles, a gradual decrease in the size of muscles (muscle atrophy) and fatigue years after the acute illness. L-citrulline is known to change muscular metabolism synthesis by raising nitric oxide (NO) levels and increasing protein synthesis. This investigator-initiated, randomised, placebo-controlled, double-blind, trial aims to demonstrate that L-citrulline positively influences muscle function and increases muscular energy production in patients with PPS. METHODS/DESIGN: Thirty ambulant PPS patients will be recruited in Switzerland. Patients will be randomly allocated to one of the two arms of the study (placebo:verum 1:1). After a 24-week run-in phase to observe natural disease history and progression, participants will be treated either with L-citrulline or placebo for 24 weeks. The primary endpoint is change in the 6-min Walking Distance Test. Secondary endpoints will include motor function measure, quantitative muscle force, quantitative muscle magnetic resonance imaging and magnetic resonance spectroscopy and serum biomarker laboratory analysis DISCUSSION: The aim of this phase IIa trial is to determine if treatment with L-citrulline shows a positive effect on clinical function and paraclinical biomarkers in PPS. If treatment with L-citrulline shows positive effects, this might represent a cost-efficient symptomatic therapy for PPS patients. TRIAL REGISTRATION: ClinicalTrial.gov, ID: NCT02801071 . Registered on 6 June 2016.
引用
- Schmidt S, Gocheva V, Zumbrunn T, et al. Treatment with L-citrulline in patients with post-polio syndrome: study protocol for a single-center, randomised, placebo-controlled, double-blind trial. Trials. 2017. PMID: 28274276. doi:10.1186/s13063-017-1829-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。